Literature DB >> 18711744

Chronic fluoxetine treatment improves ischemia-induced spatial cognitive deficits through increasing hippocampal neurogenesis after stroke.

Wen-Lei Li1, Hui-Hui Cai, Bin Wang, Ling Chen, Qi-Gang Zhou, Chun-Xia Luo, Na Liu, Xin-Sheng Ding, Dong-Ya Zhu.   

Abstract

Cognitive deficits, including spatial memory impairment, are very common after ischemic stroke. Neurogenesis in the dentate gyrus (DG) contributes to forming spatial memory in the ischemic brain. Fluoxetine, a selective serotonin reuptake inhibitor, can enhance neurogenesis in the hippocampus in physiological situations and some neurological diseases. However, whether it has effects on ischemia-induced spatial cognitive impairment and hippocampal neurogenesis has not been determined. Here we report that fluoxetine treatment (10 mg kg(-1), i.p.) for 4 weeks promoted the survival of newborn cells in the ischemic hippocampus and, consequently, attenuated spatial memory impairment of mice after focal cerebral ischemia. Disrupting hippocampal neurogenesis blocked the beneficial effect of fluoxetine on ischemia-induced spatial cognitive impairment. These results suggest that chronic fluoxetine treatment benefits spatial cognitive function recovery following ischemic insult, and the improved cognitive function is associated with enhanced newborn cell survival in the hippocampus. Our results raise the possibility that fluoxetine can be used as a drug to treat poststroke spatial cognitive deficits. 2008 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 18711744     DOI: 10.1002/jnr.21829

Source DB:  PubMed          Journal:  J Neurosci Res        ISSN: 0360-4012            Impact factor:   4.164


  42 in total

1.  Chronic fluoxetine ameliorates adolescent chronic nicotine exposure-induced long-term adult deficits in trace conditioning.

Authors:  David A Connor; Thomas J Gould
Journal:  Neuropharmacology       Date:  2017-08-02       Impact factor: 5.250

2.  Strategies for early stroke recovery: what lies ahead?

Authors:  Tomoko Kitago; Randolph S Marshall
Journal:  Curr Treat Options Cardiovasc Med       Date:  2015-01

3.  Fluoxetine ameliorates behavioral and neuropathological deficits in a transgenic model mouse of α-synucleinopathy.

Authors:  Kiren Ubhi; Chandra Inglis; Michael Mante; Christina Patrick; Anthony Adame; Brian Spencer; Edward Rockenstein; Verena May; Juergen Winkler; Eliezer Masliah
Journal:  Exp Neurol       Date:  2012-01-16       Impact factor: 5.330

4.  Nesfatin-1 Improve Spatial Memory Impairment Following Transient Global Cerebral Ischemia/Reperfusion via Inhibiting Microglial and Caspase-3 Activation.

Authors:  Sohaila Erfani; Ali Moghimi; Nahid Aboutaleb; Mehdi Khaksari
Journal:  J Mol Neurosci       Date:  2018-06-28       Impact factor: 3.444

5.  Fluoxetine Enhances Neurogenesis in Aged Rats with Cortical Infarcts, but This is not Reflected in a Behavioral Recovery.

Authors:  Xiaoyu Sun; Zhike Zhou; Tingting Liu; Mei Zhao; Shanshan Zhao; Ting Xiao; Jukka Jolkkonen; Chuansheng Zhao
Journal:  J Mol Neurosci       Date:  2015-10-16       Impact factor: 3.444

Review 6.  Improving Memory and Cognition in Individuals with Down Syndrome.

Authors:  Michael S Rafii
Journal:  CNS Drugs       Date:  2016-07       Impact factor: 5.749

7.  Chronic Fluoxetine Induces Activity Changes in Recovery From Poststroke Anxiety, Depression, and Cognitive Impairment.

Authors:  Faranak Vahid-Ansari; Paul R Albert
Journal:  Neurotherapeutics       Date:  2018-01       Impact factor: 7.620

8.  Effects of Fluoxetine on Hippocampal Neurogenesis and Neuroprotection in the Model of Global Cerebral Ischemia in Rats.

Authors:  Marina Khodanovich; Alena Kisel; Marina Kudabaeva; Galina Chernysheva; Vera Smolyakova; Elena Krutenkova; Irina Wasserlauf; Mark Plotnikov; Vasily Yarnykh
Journal:  Int J Mol Sci       Date:  2018-01-05       Impact factor: 5.923

Review 9.  Pharmacological Enhancement of Stroke Recovery.

Authors:  Amit Kumar; Tomoko Kitago
Journal:  Curr Neurol Neurosci Rep       Date:  2019-05-30       Impact factor: 5.081

Review 10.  Serotonin Selective Reuptake Inhibitors (SSRIs) and Stroke.

Authors:  F Chollet; J Rigal; P Marque; M Barbieux-Guillot; N Raposo; V Fabry; J F Albucher; J Pariente; I Loubinoux
Journal:  Curr Neurol Neurosci Rep       Date:  2018-10-23       Impact factor: 5.081

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.